Trials / Completed
CompletedNCT01351636
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients: An Open Labelled, Randomized, Multicentered, Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arotinolol Hydrochloride | Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months |
| DRUG | Non arotinolol group | Antihypertensive medications without arotinolol for 18 months |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2018-10-10
- Completion
- 2018-10-10
- First posted
- 2011-05-11
- Last updated
- 2019-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01351636. Inclusion in this directory is not an endorsement.